JP2022524218A5 - - Google Patents

Info

Publication number
JP2022524218A5
JP2022524218A5 JP2021559064A JP2021559064A JP2022524218A5 JP 2022524218 A5 JP2022524218 A5 JP 2022524218A5 JP 2021559064 A JP2021559064 A JP 2021559064A JP 2021559064 A JP2021559064 A JP 2021559064A JP 2022524218 A5 JP2022524218 A5 JP 2022524218A5
Authority
JP
Japan
Prior art keywords
aso
seq
angptl2
lna
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524218A (ja
JP7725370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026379 external-priority patent/WO2020206115A2/en
Publication of JP2022524218A publication Critical patent/JP2022524218A/ja
Publication of JP2022524218A5 publication Critical patent/JP2022524218A5/ja
Priority to JP2025131153A priority Critical patent/JP2026002846A/ja
Application granted granted Critical
Publication of JP7725370B2 publication Critical patent/JP7725370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559064A 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 Active JP7725370B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131153A JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828864P 2019-04-03 2019-04-03
US62/828,864 2019-04-03
PCT/US2020/026379 WO2020206115A2 (en) 2019-04-03 2020-04-02 Angptl2 antisense oligonucleotides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131153A Division JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2022524218A JP2022524218A (ja) 2022-04-28
JP2022524218A5 true JP2022524218A5 (cg-RX-API-DMAC7.html) 2023-04-10
JP7725370B2 JP7725370B2 (ja) 2025-08-19

Family

ID=70465458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559064A Active JP7725370B2 (ja) 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Country Status (13)

Country Link
US (1) US20220213484A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947680A2 (cg-RX-API-DMAC7.html)
JP (2) JP7725370B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149107A (cg-RX-API-DMAC7.html)
CN (1) CN113906139A (cg-RX-API-DMAC7.html)
AU (1) AU2020252374A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135794A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192733A1 (cg-RX-API-DMAC7.html)
IL (1) IL286826A (cg-RX-API-DMAC7.html)
MX (1) MX2021012098A (cg-RX-API-DMAC7.html)
SG (1) SG11202110745VA (cg-RX-API-DMAC7.html)
WO (1) WO2020206115A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3131970B1 (fr) 2022-01-14 2024-02-23 Univ D’Aix Marseille Amu Dispositif pour la simulation en chirurgie abdominale

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
JPH11341989A (ja) * 1998-03-31 1999-12-14 Sanyo Electric Co Ltd Ｄｎａ断片増幅方法、ｄｎａ断片増幅装置、微生物群測定方法、微生物群分析方法および汚染物質測定方法
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
AU4066800A (en) 1999-04-01 2000-10-23 Genetics Institute Inc. Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
WO2004046160A2 (en) 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
ATE443765T1 (de) 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
US20070072209A1 (en) * 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007085485A2 (en) 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
WO2010102058A2 (en) * 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
JP2011093896A (ja) 2009-09-30 2011-05-12 Kumamoto Univ 癌治療剤
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
RS61447B1 (sr) * 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014167529A1 (en) * 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
EP3007705A4 (en) 2013-06-12 2017-02-15 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
JP2017535552A (ja) * 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
US11077132B2 (en) * 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
JP6978774B2 (ja) 2015-11-06 2021-12-08 国立大学法人 熊本大学 心不全の予防又は治療のための医薬組成物
US11504391B1 (en) 2016-11-23 2022-11-22 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect
WO2020160163A1 (en) * 2019-01-29 2020-08-06 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression

Similar Documents

Publication Publication Date Title
JP2021513861A5 (cg-RX-API-DMAC7.html)
IL276549B1 (en) CAMK2D antisense oligonucleotides and their uses
KR101878587B1 (ko) 올리고머 및 올리고머 접합체
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP2021510511A5 (cg-RX-API-DMAC7.html)
JP2025179845A (ja) Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
IL275903B1 (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
JP2000514093A (ja) Ｃｍｖ感染症の治療のための組成物および方法
JP2025166835A (ja) Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
JP2022524218A5 (cg-RX-API-DMAC7.html)
WO2007137301A2 (en) Modulation of chrebp expression
JP2026002846A (ja) Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
EP3568481A1 (en) Antisense oligonucleotides for modulating relb expression
AU2018421460B2 (en) Therapeutic uses and methods
JP2024026274A (ja) マイクロｒｎａ関連疾患の処置のための薬学的組成物
JP7653997B2 (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023506550A (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
CN114829603A (zh) 用于抑制scn9a表达的增强寡核苷酸
EP3568479A1 (en) Antisense oligonucleotides for modulating nfkb1 expression
WO2025090254A1 (en) Adnp syndrome antisense treatment
CN121941769A (zh) Ppp1r15b rna干扰剂
HK40078456A (en) Use of sbds inhibitors for treating hepatitis b virus infection
RU2022113237A (ru) Антисмысловые олигонуклеотиды к альфа-синуклеину и их применения
WO2019038228A1 (en) OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
HK40060810A (en) Oligonucleotides for modulating atxn2 expression